Jatin Shah
2021
In 2021, Jatin Shah earned a total compensation of $1.6M as Former Executive Vice President, Chief Medical Officer at Karyopharm Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $179,078 |
|---|---|
| Option Awards | $588,826 |
| Salary | $457,980 |
| Stock Awards | $320,509 |
| Other | $41,820 |
| Total | $1,588,213 |
Shah received $588.8K in option awards, accounting for 37% of the total pay in 2021.
Shah also received $179.1K in non-equity incentive plan, $458K in salary, $320.5K in stock awards and $41.8K in other compensation.
Rankings
In 2021, Jatin Shah's compensation ranked 7,011th out of 12,415 executives tracked by ExecPay. In other words, Shah earned more than 43.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,011 out of 12,415 | 44th |
Division Manufacturing | 3,071 out of 5,501 | 44th |
Major group Chemicals And Allied Products | 1,359 out of 2,371 | 43rd |
Industry group Drugs | 1,210 out of 2,092 | 42nd |
Industry Pharmaceutical Preparations | 882 out of 1,542 | 43rd |
Source: SEC filing on April 8, 2022.
Shah's colleagues
We found five more compensation records of executives who worked with Jatin Shah at Karyopharm Therapeutics in 2021.
2021
Richard Paulson
Karyopharm Therapeutics
Chief Executive Officer
2021
Sharon Shacham
Karyopharm Therapeutics
Chief Scientific Officer
2021
Michael Kauffman
Karyopharm Therapeutics
Chief Executive Officer
2021
Michael Mason
Karyopharm Therapeutics
Chief Financial Officer
2021
Ran Frenkel
Karyopharm Therapeutics